Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Wuhan iRegene Therapeutics Starts China Trial of iPSC Cell Therapy for Parkinson’s

publication date: Feb 6, 2024

Wuhan iRegene Therapeutics has dosed the first patient in a China Phase I/II clinical trial of a novel therapy for Parkinson’s Disease. NouvNeu001 is a chemically induced human dopaminergic neuron precursor derived from iPSC stem cells. Upon transplantation, the cells establish connections with the body's existing neurons with the goal of augmenting cellular secretion functions, The trial will test the efficacy of a stereotactic bilateral intracerebral injection of NouvNeu001 in patients with moderate to advanced Parkinson's disease. iRegene says NouvNeu001 is the world's first iPSC-based, chemically induced universal cell therapy product. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital